AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes

Daniel J. Hui(Children's Hospital of Philadelphia), Etiena Basner‐Tschakarjan(Children's Hospital of Philadelphia), Hildegund C.J. Ertl(The Wistar Institute), Katherine A. High(Spark Therapeutics (United States)), Lacramioara Ivanciu(Children's Hospital of Philadelphia), Rodney M. Camire(Children's Hospital of Philadelphia), Federico Mingozzi(Spark Therapeutics (United States)), Shyrie C Edmonson(Children's Hospital of Philadelphia), Gary C. Pien(Children's Hospital of Philadelphia), Gregory M. Podsakoff(Mundipharma (United Kingdom))
Molecular Therapy — Methods & Clinical Development
January 1, 2015
10.1038/mtm.2015.29
Cited by 83

Related Papers

Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
|New England Journal of Medicine|2008|2.1k
Gene therapy comes of age
|Science|2018|1.4k
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|864
Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration
|Molecular Therapy|2009|551
Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial
|The Lancet|2016|464